[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Capricor Therap (CAPR)

Capricor Therap (CAPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 584,878
  • Shares Outstanding, K 58,139
  • Annual Sales, $ 0 K
  • Annual Income, $ -105,040 K
  • EBIT $ -135 M
  • EBITDA $ -133 M
  • 60-Month Beta 0.54
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.95

Options Overview Details

View History
  • Implied Volatility 139.09% (+5.15%)
  • Historical Volatility 370.50%
  • IV Percentile 58%
  • IV Rank 19.38%
  • IV High 456.20% on 12/02/25
  • IV Low 62.85% on 01/22/26
  • Expected Move (DTE 7) 0.96 (9.55%)
  • Put/Call Vol Ratio 0.62
  • Today's Volume 24,850
  • Volume Avg (30-Day) 18,248
  • Put/Call OI Ratio 0.55
  • Today's Open Interest 183,118
  • Open Int (30-Day) 202,563
  • Expected Range 9.10 to 11.02

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.61
  • Number of Estimates 5
  • High Estimate $-0.40
  • Low Estimate $-0.74
  • Prior Year $-0.54
  • Growth Rate Est. (year over year) -12.96%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.96 +238.85%
on 07/30/26
10.61 -5.47%
on 08/27/26
+3.46 (+52.66%)
since 07/28/26
3-Month
2.96 +238.85%
on 07/30/26
30.93 -67.57%
on 06/25/26
-19.08 (-65.54%)
since 05/28/26
52-Week
2.96 +238.85%
on 07/30/26
40.37 -75.15%
on 12/03/25
+3.77 (+60.22%)
since 08/28/25

Most Recent Stories

More News
Kaplan Fox Encourages Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) to Contact the Firm Before Lead Plaintiff Deadline on September 28, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

BAC : 61.35 (+0.29%)
CAPR : 10.03 (-0.30%)
CAPR DEADLINE: SueWallSt Reminds Capricor Therapeutics, Inc. Investors of Upcoming Securities Class Action Deadline

Capricor's Chief Executive Officer and Chief Financial Officer are named as individual defendants in a securities class action alleging they controlled and certified public statements about the HOPE-3...

CAPR : 10.03 (-0.30%)
Kaplan Fox Encourages Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) to Contact the Firm to Learn About Their Legal Rights

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

BAC : 61.35 (+0.29%)
CAPR : 10.03 (-0.30%)
Capricor Therapeutics, Inc. (CAPR) Class Action Lawsuit Seeks Recovery for Investors; September 28, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP

Did you buy CAPR securities between December 17, 2025 and July 26, 2026?

CAPR : 10.03 (-0.30%)
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR

LOS ANGELES , Aug. 27, 2026 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR...

CAPR : 10.03 (-0.30%)
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

LOS ANGELES , Aug. 27, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP  ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor...

CAPR : 10.03 (-0.30%)
Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - August 26, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies...

CAPR : 10.03 (-0.30%)
Kaplan Fox Alerts Investors to an Upcoming Deadline of September 28, 2026 in the Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Class Action

NEW YORK, NY - August 26, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or the “Company”)...

BAC : 61.35 (+0.29%)
CAPR : 10.03 (-0.30%)
INVESTOR ALERT: Capricor Therapeutics, Inc. (CAPR) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

CAPR : 10.03 (-0.30%)
CAPR Shareholder Alert: Capricor Therapeutics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

A securities class action alleges Capricor Therapeutics failed to disclose that it changed the pre-specified statistical analysis plan for its Phase 3 HOPE-3 trial without FDA agreement, leaving...

CAPR : 10.03 (-0.30%)

Business Summary

Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based...

See More

Key Turning Points

3rd Resistance Point 12.52
2nd Resistance Point 11.57
1st Resistance Point 10.81
Last Price 10.03
1st Support Level 9.10
2nd Support Level 8.15
3rd Support Level 7.39

See More

52-Week High 40.37
Fibonacci 61.8% 26.08
Fibonacci 50% 21.66
Fibonacci 38.2% 17.25
Last Price 10.03
52-Week Low 2.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.